The drug was well tolerated and there were no serious adverse events increasing potency.

NexBio has phase Ib trial phase Ib trial with increasing single and multiple doses of DAS181 in healthy volunteers. The drug was well tolerated and there were no serious adverse events increasing potency . NexBio recently announced.

The article is amyloid imaging in aging and dementia. To testing the amyloid hypothesis vivo by GD Rabinovici and WJ Jagust. It appears in Behavioural Neurology, Issues 1-2 , followed by IOS Press publishes.

For humans grimace scale set up to identify ache in humans or animals.

Dermatol 146[ 4]:406-411.